Literature DB >> 6154062

Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.

J Trachtenberg, L L Hicks, P C Walsh.   

Abstract

To gain insight into the mechanism by which steroidal hormones influence the development of canine prostatic hyperplasia, nuclear and cytosolic androgen- and estrogen-receptor content, as measured under exchange conditions by the binding of [(3)H]R1881 (methyltrienolone) and [(3)H]estradiol, respectively, were quantitated in the prostates of purebred beagles of known age. In young dogs with spontaneously arising and experimentally induced (androstanediol plus estradiol treatment) prostatic hyperplasia, nuclear, but not cytosolic, prostatic androgen-receptor content was significantly greater than that determined in the normal prostates of age-matched dogs (3,452+/-222 and 4,035+/-274 fmol/mg DNA vs. 2,096+/-364 fmol/mg DNA, respectively). No differences were observed between the androgen-receptor content of the normal prostates of young dogs and the hyperplastic prostates of old dogs. The cytosolic and nuclear estrogen-receptor content of spontaneously arising prostatic hyperplasia in both young and old animals was similar to that found in normal prostates. The administration of estradiol plus androstanediol to castrate dogs significantly increased the prostatic nuclear androgen-receptor content over that found in dogs treated only with androstanediol. This estradiol-associated increase in nuclear androgen-receptor content was accompanied by the development of benign prostatic hyperplasia. Estradiol treatment of castrate dogs resulted in an increase in prostatic nuclear estrogen-receptor content, in the appearance of a putative prostatic cytosolic progesterone receptor, and in an alteration of the epithelium of the prostate to one characterized by squamous metaplasia. Treatment of castrate dogs with both estradiol and androstanediol resulted in a reduction in prostatic nuclear estrogen-receptor content, disappearance of the progesterone receptor, and loss of squamous metaplasia. An increase in nuclear androgen-receptor content, thus, appears to be an important event in the development of both spontaneously arising and experimentally induced canine prostatic hyperplasia. The mechanism of androgen-estrogen synergism in the experimental induction of canine benign prostatic hyperplasia may be explained by estradiol-mediated increases in nuclear androgen-receptor content. Because androstanediol blocked certain estradiol-mediated events within the prostate, a negative feedback mechanism may exist in which the response of the canine prostate to estrogens is modulated by rising levels of androgen.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154062      PMCID: PMC371435          DOI: 10.1172/JCI109757

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

Review 1.  Current models of steroid hormone action: a critique.

Authors:  J Gorski; F Gannon
Journal:  Annu Rev Physiol       Date:  1976       Impact factor: 19.318

2.  Identification of limited capacity androgen binding components in nuclear and cytoplasmic fractions of canine prostate.

Authors:  R W Boesel; R W Klipper; S A Shain
Journal:  Endocr Res Commun       Date:  1977

3.  Mechanisms regulating the concentration and the conformation of progesterone receptor(s) in the uterus.

Authors:  E Milgrom; L Thi; M Atger; E E Baulieu
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

4.  Progesterone and progesterone receptors in experimental breast cancer.

Authors:  K B Horwitz; W L McGuire
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

5.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

6.  Control of uterine estrogen receptor levels by progesterone.

Authors:  A J Hsueh; E J Peck; J H Clark
Journal:  Endocrinology       Date:  1976-02       Impact factor: 4.736

7.  Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog.

Authors:  R E Gloyna; P K Siiteri; J D Wilson
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

8.  The induction of prostatic hypertrophy in the dog with androstanediol.

Authors:  P C Walsh; J D Wilson
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

9.  Androgen receptor content of the normal and hyperplastic canine prostate.

Authors:  S A Shain; R W Boesel
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

10.  Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues.

Authors:  M Menon; C E Tananis; L L Hicks; E F Hawkins; M G McLoughlin; P C Walsh
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

View more
  9 in total

Review 1.  Prostate gland: structure, functions and regulation.

Authors:  V L Kumar; P K Majumder
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

2.  Side gland of Suncus murinus as a new model of sebaceous gland: 5 alpha-reductase, androgen receptor, and nuclear androgen content in male and female animals.

Authors:  S Komada; S Itami; S Kurata; S Takayasu
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 3.  Estrogenic environmental chemicals and drugs: mechanisms for effects on the developing male urogenital system.

Authors:  Julia A Taylor; Catherine A Richter; Rachel L Ruhlen; Frederick S vom Saal
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-30       Impact factor: 4.292

4.  Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH.

Authors:  G Tolis; M Koutsilieris; R Herrera; A Stellos; A Martinez; M Dufresne
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. II. Endocrinological analysis.

Authors:  K Okada; K Oishi; O Yoshida; K Sudo; M Kawase; R Nakayama
Journal:  Urol Res       Date:  1988

6.  Consumption of high ω-3 fatty acid diet suppressed prostate tumorigenesis in C3(1) Tag mice.

Authors:  Juliana A Akinsete; Gabriela Ion; Theodore R Witte; W Elaine Hardman
Journal:  Carcinogenesis       Date:  2011-10-31       Impact factor: 4.944

7.  Changes in specific serum biomarkers during the induction of prostatic hyperplasia in dogs.

Authors:  Kamran Golchin-Rad; Asghar Mogheiseh; Saeed Nazifi; Mohammad Saeed Ahrari Khafi; Nooshin Derakhshandeh; Mohammad Abbaszadeh-Hasiri
Journal:  BMC Vet Res       Date:  2019-12-05       Impact factor: 2.741

8.  The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A.

Authors:  Shuangshuang Wu; Dongyan Huang; Xin Su; Han Yan; Aicui Ma; Lei Li; Jianhui Wu; Zuyue Sun
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

9.  Resveratrol Attenuates the Proliferation of Prostatic Stromal Cells in Benign Prostatic Hyperplasia by Regulating Cell Cycle Progression, Apoptosis, Signaling Pathways, BPH Markers, and NF- κB Activity.

Authors:  Jowon Jang; Junhui Song; Jiyun Lee; Sung-Kwon Moon; Bokyung Moon
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.